Open AccessIdentification of a novel tedizolid resistance mutation in rpoB of MRSA after in vitro serial passage
Author(s) -
Tianwei Shen,
Kelsi Penewit,
Adam Waalkes,
Libin Xu,
Stephen J. Salipante,
Abhinav Nath,
Brian J. Werth
Publication year - 2020
Publication title -
the journal of antimicrobial chemotherapy/journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkaa422
Subject(s) - rpob , linezolid , biology , quinupristin , microbiology and biotechnology , mutant , cross resistance , antibiotic resistance , minimum inhibitory concentration , antimicrobial , genetics , antibiotics , bacteria , staphylococcus aureus , gene , vancomycin , 16s ribosomal rna
Tedizolid is an oxazolidinone antimicrobial with activity against Gram-positive bacteria, including MRSA. Tedizolid resistance is uncommon and tedizolid's capacity to select for cross-resistance to other antimicrobials is incompletely understood. The objective of this study was to further explore the phenotypic and genetic basis of tedizolid resistance in MRSA.